# Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

> **NCT01854827** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 30 (actual)

## Conditions studied

- Biliary Atresia

## Interventions

- **DRUG:** Intravenous immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT01854827
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854827, "Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01854827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*